Skyhawk Therapeutics reported that its RNA-splicing Huntington’s disease program, SKY-0515, improved symptoms in extension results from a Phase 1/2 study, supporting movement toward pivotal development. The company highlighted a 1.59-point improvement on a disease scale in the extension data set. Separately, Denmark-based Teitur Trophics reported positive Phase I Parkinson’s results for its peptide therapy TT-P34, with the key early signal focused on achieving central nervous system exposure and showing target-related protein changes in cerebrospinal fluid. Together, the two readouts underscore a shared development theme in neurodegeneration: demonstrating pharmacology in the brain or spinal compartment early—alongside tolerability—before scaling into larger efficacy studies. For clinical strategists, the common operational milestone is CNS “hit” evidence, whether via RNA-splicing effects or peptide-driven reactivation of CREB and lysosomal/mitochondrial pathways.